DE69019111T2 - Ascorbinsäure-Tocopheryl-Phosphatdiester zur Hemmung der Maillard-Reaktion. - Google Patents

Ascorbinsäure-Tocopheryl-Phosphatdiester zur Hemmung der Maillard-Reaktion.

Info

Publication number
DE69019111T2
DE69019111T2 DE69019111T DE69019111T DE69019111T2 DE 69019111 T2 DE69019111 T2 DE 69019111T2 DE 69019111 T DE69019111 T DE 69019111T DE 69019111 T DE69019111 T DE 69019111T DE 69019111 T2 DE69019111 T2 DE 69019111T2
Authority
DE
Germany
Prior art keywords
inhibiting
ascorbic acid
maillard reaction
phosphate diester
tocopheryl phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69019111T
Other languages
English (en)
Other versions
DE69019111D1 (de
Inventor
Jun Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69019111D1 publication Critical patent/DE69019111D1/de
Publication of DE69019111T2 publication Critical patent/DE69019111T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE69019111T 1989-11-21 1990-11-20 Ascorbinsäure-Tocopheryl-Phosphatdiester zur Hemmung der Maillard-Reaktion. Expired - Fee Related DE69019111T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1304479A JP2854631B2 (ja) 1989-11-21 1989-11-21 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤

Publications (2)

Publication Number Publication Date
DE69019111D1 DE69019111D1 (de) 1995-06-08
DE69019111T2 true DE69019111T2 (de) 1995-08-31

Family

ID=17933520

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69019111T Expired - Fee Related DE69019111T2 (de) 1989-11-21 1990-11-20 Ascorbinsäure-Tocopheryl-Phosphatdiester zur Hemmung der Maillard-Reaktion.

Country Status (8)

Country Link
EP (1) EP0430045B1 (de)
JP (1) JP2854631B2 (de)
KR (1) KR910009272A (de)
AT (1) ATE121939T1 (de)
CA (1) CA2029420C (de)
DE (1) DE69019111T2 (de)
DK (1) DK0430045T3 (de)
ES (1) ES2071725T3 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05286848A (ja) * 1992-04-10 1993-11-02 Senju Pharmaceut Co Ltd 浴用剤
CA2129509A1 (en) * 1993-09-10 1995-03-11 Kazumi Ogata Pharmaceutical composition for renal disorder and a dialysis solution for extracorporeal hemodialysis
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
JP3362501B2 (ja) * 1994-04-28 2003-01-07 千寿製薬株式会社 角膜障害治療剤
JP3396953B2 (ja) * 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
JPH07330501A (ja) 1994-06-14 1995-12-19 Senju Pharmaceut Co Ltd 肝保存剤および肝保存方法
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
CA2152693A1 (en) * 1994-08-05 1996-02-06 Kazumi Ogata Therapeutic composition for pancreatitis
US5795912A (en) * 1995-04-26 1998-08-18 Senju Pharmaceutical, Co., Ltd. Therapeutic composition for corneal impairment
CA2179940A1 (en) * 1995-07-18 1997-01-19 Kazumi Ogata Antiallergic composition comprising a phosphoric diester compound
CA2186654A1 (en) * 1995-10-13 1997-04-14 Masayuki Nakamura Phosphoric diester
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO1999039716A1 (fr) * 1998-02-03 1999-08-12 Senju Pharmaceutical Co., Ltd. Substances preventives et medicaments destines aux maladies neurodegeneratives
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
CN1547475B (zh) 2001-07-27 2010-12-15 生命健康科学有限公司 含电子转移试剂的磷酸酯衍生物的皮肤制剂
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
WO2003026673A1 (en) * 2001-09-26 2003-04-03 Vital Health Sciences Pty Ltd. Modulation of vitamin storage
EP1458360B1 (de) 2001-12-19 2011-05-11 Novartis AG Pulmonale verabreichung von aminoglykosiden
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
DE602005025979D1 (de) 2004-03-03 2011-03-03 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
WO2006092025A1 (en) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Compounds having lipid lowering properties
ES2557475T3 (es) 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
BR112012024835A2 (pt) 2010-03-30 2016-06-07 Phosphagenics Ltd adesivo de distribuição transdérmica
EP2685992A4 (de) 2011-03-15 2014-09-10 Phosphagenics Ltd Aminochinoline als kinasehemmer
CN104297412B (zh) * 2014-10-17 2015-12-02 徐州工程学院 一种蛋白粉新鲜度的测定方法
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
KR102647670B1 (ko) 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59219295A (ja) * 1983-05-30 1984-12-10 Senjiyu Seiyaku Kk リン酸ジエステルまたはその塩およびそれらの製造法
JPS62205091A (ja) * 1986-03-04 1987-09-09 Senjiyu Seiyaku Kk 新規なリン酸ジエステルならびにその塩、その製造法およびそれを含有する製剤
JPH0781138B2 (ja) * 1986-12-02 1995-08-30 株式会社資生堂 抗酸化剤
JP2546687B2 (ja) * 1987-09-11 1996-10-23 千寿製薬株式会社 リン酸ジエステルまたはその塩からなる抗酸化剤
PH25859A (en) * 1988-01-11 1991-12-02 Takeda Chemical Industries Ltd Composition for treatment of ischemic disorder

Also Published As

Publication number Publication date
EP0430045A3 (en) 1991-11-06
DK0430045T3 (da) 1995-07-17
KR910009272A (ko) 1991-06-28
ATE121939T1 (de) 1995-05-15
EP0430045A2 (de) 1991-06-05
CA2029420A1 (en) 1991-05-22
EP0430045B1 (de) 1995-05-03
JP2854631B2 (ja) 1999-02-03
JPH03161444A (ja) 1991-07-11
ES2071725T3 (es) 1995-07-01
DE69019111D1 (de) 1995-06-08
CA2029420C (en) 2000-09-19

Similar Documents

Publication Publication Date Title
ATE121939T1 (de) Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion.
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
DE69030616D1 (de) Pharmazeutische Zusammensetzungen zur Hemmung der Maillardreaktion
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
ATE71092T1 (de) Hydroxybutenolid-derivate, ihre herstellung und ihre verwendung.
DK288787D0 (da) Kondenserede imidazo-heterocycliske forbindelser, fremgangsmaade til deres fremstilling, og deres anvendelse som laegemidler
DE3786865T2 (de) Aminosäurederivate enthaltende antikonvulsive Zusammensetzungen und Verwendung dieser Aminosäurederivate.
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
PT85866A (en) Process for the preparation of therapeutic agents for the treatment of peptic ulcers containing 1,2,3,6-tetrahydro-3-methyl-1-(5-oxohexyl)-7-propyl-purine,6-dione and their derivatives
IE890648L (en) 4,5,6,7-Tetrahydroisothiazolo (4,5-c)pyridine derivatives and isomere
IT1223395B (it) Composti ad attivita' cardiovascolare
LT2199B (lt) 2-triazolidinono dariniu gavimo budas
ES2057110T3 (es) Utilizacion de isoxazolinonas como farmacos con accion sobre el cerebro.
EP0301466A3 (en) Uricosuric composition
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee